Special Issue "Dendritic Cell Vaccine"
A special issue of Vaccines (ISSN 2076-393X).
Deadline for manuscript submissions: closed (30 June 2013)
Dr. Brian J. Czerniecki
Department of Surgery, Hospital of the University of Pennsylvania, 3 Perelman Center 3400 Civic Center Drive, Philadelphia, PA 19104, USA
Interests: dendritic cells, toll like receptors, tumor immunology, innate immunity, T cells
With the FDA approval of Sipuleucel-T for prostate cancer dendritic cell vaccines have moved into the forefront of cancer vaccines. There are many controversies surrounding the use of dendritic cell vaccines for therapy such as the phenotype, cytokine and chemokine production, sites and modes of delivery, and best way to load and target antigens to these cells. There continue to be many clinical trials using various types of activated dendritic cells for the treatment and prevention of numerous diseases especially cancer and some infectious diseases. We would like in this special issue on dendritic cell vaccines to point out some of the specific uses of dendritic cells and opportunities to improve dendritic cell vaccines in combinations with other therapies, chemotherapy, radiation therapy, chemokines and cytokines to alter the tumor microenvironment, antibodies, and reagents that are in trial that release “brakes” from the immune response. We would also use this forum to discuss the role of dendritic cell vaccines in secondary prevention of cancer: targeting stem cells, circulating tumor cells, dormant tumor cells, and senescent tumor cells. Lastly factors that affect the accumulation of subtypes of dendritic cells in the tumor environment and factors that can change dendritic cells in the tumor environment would be welcome discussions. The book will include original research, review articles, commentaries and editorials discussing the use of dendritic cell vaccines in therapy.
Dr. Brian J. Czerniecki
Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. Papers will be published continuously (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.
Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are refereed through a peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Vaccines is an international peer-reviewed Open Access quarterly journal published by MDPI.
Please visit the Instructions for Authors page before submitting a manuscript. For the first couple of issues the Article Processing Charge (APC) will be waived for well-prepared manuscripts. English correction and/or formatting fees of 250 CHF (Swiss Francs) will be charged in certain cases for those articles accepted for publication that require extensive additional formatting and/or English corrections.
- dendritic cells
- tumor immunology
- tumor microenvironment
- immature myeloid cells
- toll like receptors
Vaccines 2013, 1(4), 527-549; doi:10.3390/vaccines1040527
Received: 7 August 2013; in revised form: 18 October 2013 / Accepted: 7 November 2013 / Published: 21 November 2013| Download PDF Full-text (695 KB) | View HTML Full-text | Download XML Full-text
Vaccines 2013, 1(4), 444-462; doi:10.3390/vaccines1040444
Received: 22 July 2013; in revised form: 31 August 2013 / Accepted: 26 September 2013 / Published: 16 October 2013| Download PDF Full-text (1109 KB) | View HTML Full-text | Download XML Full-text
Last update: 8 January 2013